首頁 > 市場調查報告書 > 製藥

非專利藥糖尿病生物製劑生技仿製藥

市場調查報告書

商品編碼

1464001

短效胰島素市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物（Apidra、Novolog、Humalog、Novolin 等）、按應用（1 型糖尿病、2 型糖尿病）、按地區和競爭細分, 2019 -2029F

Short-Acting Insulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs (Apidra, Novolog, Humalog, Novolin, Others), By Application (Type 1 Diabetes, Type 2 Diabetes), By Region and Competition, 2019-2029F

出版日期: 2024年04月15日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年全球短效胰島素市場估值為67.5 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為4.05%。且重要的組成部分部門，滿足糖尿病患者的需求。短效胰島素，也稱為常規或速效胰島素，在控制血糖水平方面發揮關鍵作用，特別是在進餐期間。這個市場圍繞著短效胰島素產品的生產、分銷和使用，這對於需要快速有效的胰島素作用的糖尿病患者來說是必不可少的。的不斷上升全世界的糖尿病。隨著糖尿病變得越來越普遍，特別是隨著久坐生活方式和肥胖的增加，對短效胰島素的需求激增。這種胰島素變體對於控制餐後血糖水平至關重要，可以根據用餐時間的要求快速起效。市場透過提供各種配方和遞送方法來回應這種不斷成長的需求，以確保糖尿病患者的有效血糖管理。胰島素輸送系統和配方的技術進步是短效胰島素市場的另一個重要驅動力。胰島素筆、幫浦和更精細的胰島素類似物等創新提高了胰島素給藥的便利性和精確性。患者受益於這些進步，因為它們有助於提高依從性、減少注射相關不適以及更好的整體血糖控制。製造商競相推出新技術和配方，形成推動市場發展的競爭格局。此外，市場受到日益重視個人化和以患者為中心的糖尿病護理的影響。根據個人需求和生活方式量身訂做胰島素治療方案是當務之急，從而開發出更適合患者的胰島素輸送選擇。這不僅包括設備，還包括胰島素配方本身，重點是最佳化藥物動力學以模擬生理胰島素反應。短效胰島素市場順應了這些趨勢，提供多樣化的選擇，以滿足日益多樣化的患者群體的偏好和要求。

市場動態也受到胰島素產品監管環境的影響。嚴格的監管標準確保短效胰島素製劑的安全性、有效性和品質。市場參與者投資研發以滿足這些標準，同時也在新興市場探索監管批准的機會。監管合規性和對品質標準的遵守是影響市場競爭格局以及醫療保健專業人員和患者之間信任程度的關鍵方面。此外，短效胰島素市場的特點是旨在開發下一代胰島素產品的強勁研究活動。這包括努力創造超速效胰島素，更接近模仿生理胰島素反應，提供更精確和快速的起效。對改進配方和輸送系統的追求反映了市場參與者對增強患者整體糖尿病管理體驗的承諾。

主要市場促進因素

糖尿病盛行率上升

個人化糖尿病護理

主要市場挑戰

成本上升

訪問差異

依從性問題

技術差距

主要市場趨勢

先進的輸送系統

生物相似藥市場擴張

數位健康整合

連續血糖監測協作

細分市場洞察

藥物見解

應用洞察

區域洞察

Global Short-Acting Insulin Market was valued at USD 6.75 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.05% through 2029. The Short-Acting Insulin Market is a dynamic and crucial component of the global healthcare sector, catering to the needs of individuals with diabetes. Short-acting insulin, also known as regular or fast-acting insulin, plays a pivotal role in managing blood glucose levels, particularly during mealtime. This market revolves around the production, distribution, and utilization of short-acting insulin products, which are indispensable for people with diabetes who require rapid and efficient insulin action.One of the primary factors driving the Short-Acting Insulin Market is the escalating prevalence of diabetes worldwide. As diabetes becomes more prevalent, especially with the rise in sedentary lifestyles and obesity, the demand for short-acting insulin has surged. This insulin variant is essential for controlling postprandial glucose levels, offering a rapid onset of action that aligns with mealtime requirements. The market responds to this growing demand by providing various formulations and delivery methods to ensure effective glucose management for individuals with diabetes. Technological advancements in insulin delivery systems and formulations represent another significant driver in the Short-Acting Insulin Market. Innovations such as insulin pens, pumps, and more refined insulin analogs enhance the convenience and precision of insulin administration. Patients benefit from these advancements as they contribute to improved adherence, reduced injection-related discomfort, and better overall glycemic control. Manufacturers compete to introduce novel technologies and formulations, fostering a competitive landscape that propels the market's evolution. Moreover, the market is influenced by an increased emphasis on personalized and patient-centric diabetes care. Tailoring insulin regimens to individual needs and lifestyles is a priority, leading to the development of more patient-friendly insulin delivery options. This includes not only the devices but also the insulin formulations themselves, with a focus on optimizing pharmacokinetics to mimic the physiological insulin response. The Short-Acting Insulin Market aligns with these trends, offering diverse options to suit the preferences and requirements of an increasingly diverse patient population.

Market dynamics are also shaped by the regulatory environment governing insulin products. Stringent regulatory standards ensure the safety, efficacy, and quality of short-acting insulin formulations. Market players invest in research and development to meet these standards while also exploring opportunities for regulatory approval in emerging markets. Regulatory compliance and adherence to quality standards are critical aspects that influence the market's competitive landscape and the level of trust among healthcare professionals and patients. Furthermore, the Short-Acting Insulin Market is characterized by robust research activities aimed at developing next-generation insulin products. This includes efforts to create ultra-rapid-acting insulins that more closely mimic the physiological insulin response, providing an even more precise and rapid onset of action. The pursuit of improved formulations and delivery systems reflects the commitment of market players to enhance the overall diabetes management experience for patients.

Key Market Drivers

Rising Diabetes Prevalence

The driving force behind the growth of the Short-Acting Insulin Market is the escalating prevalence of diabetes on a global scale. With diabetes reaching epidemic proportions, particularly type 2 diabetes linked to sedentary lifestyles and obesity, the demand for effective insulin management has surged. Short-acting insulin, known for its rapid onset and crucial role in controlling postprandial glucose levels, becomes indispensable for individuals requiring immediate and efficient insulin action during mealtime.

As more people are diagnosed with diabetes, the need for precise glucose control becomes paramount to prevent complications. Short-acting insulin addresses this need by offering a rapid response to elevated blood glucose levels after meals. The market aligns with this demand by providing various formulations and delivery methods to cater to diverse patient needs.

The rising prevalence of diabetes also amplifies the market's significance in preventing diabetes-related complications. Efficient glucose management, achieved through short-acting insulin, is crucial for preventing cardiovascular issues, kidney problems, and other diabetes-related complications. Consequently, the Short-Acting Insulin Market becomes an integral component of diabetes care, ensuring that individuals have access to advanced and effective insulin solutions to better manage their condition and improve their overall quality of life.

Personalized Diabetes Care

The Short-Acting Insulin Market is experiencing a transformative shift driven by the increasing emphasis on personalized diabetes care. As healthcare moves towards a more patient-centric approach, tailoring diabetes management strategies to individual needs becomes paramount, and short-acting insulin plays a pivotal role in this paradigm.

Personalized diabetes care recognizes the unique characteristics of each patient, including lifestyle, dietary habits, and insulin sensitivity. Short-acting insulin formulations and delivery methods are diversified to accommodate these individual factors, ensuring a tailored and precise approach to glycemic control. This customization not only enhances treatment efficacy but also improves patient adherence and satisfaction. Advanced insulin delivery systems, such as insulin pens and pumps, provide patients with options that align with their preferences and lifestyle. These technologies contribute to a more convenient and comfortable insulin administration experience, fostering better adherence to treatment plans. Additionally, the development of novel insulin analogs with specific pharmacokinetic profiles allows healthcare providers to fine-tune insulin regimens based on individual patient needs, optimizing glycemic control.

The shift towards personalized diabetes care represents a paradigmatic evolution in diabetes management. The Short-Acting Insulin Market, by offering a diverse range of options that can be tailored to individual requirements, stands at the forefront of this transformation, ensuring that patients receive not only effective but also personalized solutions for their diabetes treatment. This trend is likely to shape the future landscape of diabetes care, emphasizing precision and patient-centric approaches within the Short-Acting Insulin Market.

Key Market Challenges

Rising Costs

The Short-Acting Insulin Market faces a significant challenge in the form of rising costs associated with production and research. The complexity of insulin manufacturing processes, coupled with the need for continual research and development for innovative formulations and delivery systems, contributes to increased production expenses. These rising costs impact the affordability of short-acting insulin, potentially limiting access for patients. As insulin is a life-sustaining medication for those with diabetes, addressing the challenge of escalating costs becomes crucial to ensure widespread availability and affordability, ultimately promoting better glycemic control and overall diabetes management.

Access Disparities

Access disparities pose a substantial challenge in the Short-Acting Insulin Market, contributing to unequal global health outcomes. Limited access to affordable insulin in certain regions creates significant disparities in diabetes management. Economic factors, healthcare infrastructure variations, and regulatory hurdles contribute to these disparities. The high costs associated with insulin production and distribution further exacerbate the accessibility issue, preventing many individuals from obtaining essential short-acting insulin. Addressing access challenges is crucial to ensure that all individuals with diabetes, regardless of geographic location or socioeconomic status, can access and afford the life-saving medication needed for effective glycemic control and overall well-being.

Adherence Issues

Adherence issues present a significant challenge for the Short-Acting Insulin Market, impacting the effectiveness of diabetes management. Patient adherence to prescribed insulin regimens, including timing and dosage, is crucial for achieving optimal glycemic control. Factors such as fear of injections, inconvenience, or lack of understanding can contribute to non-adherence. This challenge may lead to suboptimal blood glucose control, increasing the risk of complications. Strategies addressing patient education, personalized treatment plans, and the development of more user-friendly delivery systems are essential to overcome adherence issues, ensuring that individuals with diabetes can effectively incorporate short-acting insulin into their daily routines.

Technological Gaps

Technological gaps pose a challenge for the Short-Acting Insulin Market, impacting the widespread adoption of advanced insulin delivery systems. While innovations like insulin pumps and pens enhance convenience and precision, accessibility remains an issue in certain regions. Limited technological infrastructure and awareness hinder the adoption of these advancements, leading to disparities in diabetes care. Bridging technological gaps requires efforts to improve healthcare infrastructure, educate healthcare providers and patients, and ensure affordability of advanced insulin delivery technologies. Overcoming these challenges is crucial to ensure that individuals globally can benefit from the latest technological advancements in short-acting insulin therapy, optimizing diabetes management.

Key Market Trends

Advanced Delivery Systems

Advanced delivery systems represent a prominent trend in the Short-Acting Insulin Market, reflecting a shift towards enhanced patient experience and improved glycemic control. Innovations such as insulin pens, pumps, and smart devices are gaining traction, offering convenient and precise administration. These technologies provide more flexibility, reduce injection-related discomfort, and improve overall adherence to insulin regimens. The trend emphasizes a patient-centric approach, focusing on user-friendly solutions that align with individual preferences and lifestyles. As the market continues to prioritize technological advancements, the integration of more sophisticated delivery systems is expected to play a pivotal role in shaping the future landscape of short-acting insulin therapy.

Biosimilar Market Expansion

The expansion of the biosimilar market is a notable trend in the Short-Acting Insulin Market, offering increased options for individuals with diabetes. Biosimilar short-acting insulin products, which mimic the properties of existing insulin formulations, contribute to market competitiveness and affordability. This trend fosters a more competitive landscape, potentially lowering overall insulin costs and enhancing accessibility. As more biosimilars receive regulatory approval and enter the market, the trend supports the goal of providing diverse and cost-effective insulin options. The biosimilar market expansion aligns with efforts to address the rising costs and access disparities associated with short-acting insulin, making diabetes management more sustainable for a broader population.

Digital Health Integration

Digital health integration is a prominent trend shaping the Short-Acting Insulin Market, bringing technology into the forefront of diabetes management. The incorporation of digital health tools, such as smartphone apps, continuous glucose monitoring (CGM) systems, and smart insulin pens, enhances the overall patient experience. These technologies provide real-time data, personalized insights, and convenient ways to monitor and administer short-acting insulin. The trend fosters a more connected and proactive approach to diabetes care, empowering individuals to make informed decisions. As the Short-Acting Insulin Market embraces digital solutions, the synergy between technology and insulin therapy is poised to revolutionize diabetes management for improved outcomes.

Continuous Glucose Monitoring Collaboration

The trend of collaboration with continuous glucose monitoring (CGM) systems is reshaping the Short-Acting Insulin Market. Integration with CGM technologies allows for real-time glucose monitoring, enabling more precise insulin dosing decisions. This collaborative trend enhances the synergy between short-acting insulin administration and glucose control, optimizing glycemic management. Patients benefit from a more streamlined and personalized approach, as CGM data informs insulin dosing adjustments in response to fluctuating glucose levels. The trend reflects a commitment to comprehensive diabetes care, emphasizing the importance of combining advanced insulin therapies with continuous monitoring solutions for more effective and patient-centric management of diabetes.

Segmental Insights

Drugs Insights

Basedon the Drugs, Apidra, a brand of short-acting insulin (insulin glulisine), has established dominance in the market due to its rapid onset and shorter duration of action, making it an effective option for controlling postprandial glucose levels. Its quick response aligns with mealtime requirements, providing flexibility and precision in insulin dosing. Apidra's formulation reduces the risk of hypoglycemia and offers a more convenient treatment option for individuals with diabetes. With a proven track record and widespread acceptance, Apidra has become a preferred choice for healthcare providers, contributing to its dominance in the Short-Acting Insulin Market.

Application Insights

Type 1 diabetes dominance in the Short-Acting Insulin Market is rooted in the essential role short-acting insulin plays in managing this autoimmune condition. Individuals with type 1 diabetes lack natural insulin production, requiring external insulin to regulate glucose levels. Short-acting insulin, with its rapid onset, is crucial for addressing immediate postprandial glucose spikes. The precision in timing and dosage aligns with the dynamic insulin needs in type 1 diabetes, providing effective control. The prevalence of type 1 diabetes globally sustains the demand for short-acting insulin, solidifying its dominance in the market as a foundational component of type 1 diabetes management.

Regional Insights

North America's dominance in the Short-Acting Insulin Market is attributed to several factors. The region exhibits a high prevalence of diabetes, creating a substantial patient pool requiring insulin therapy. Robust healthcare infrastructure, advanced research facilities, and a well-established regulatory framework contribute to the development and adoption of innovative short-acting insulin formulations and delivery systems. Additionally, favorable reimbursement policies and a high level of awareness among healthcare professionals and patients enhance the market's growth. The presence of major pharmaceutical companies focusing on diabetes management further cements North America's position as a dominant player in the Short-Acting Insulin Market.

Key Market Players

Novo Nordisk AS

Sanofi SA

Eli Lilly Co

Biocon Ltd

Wockhardt Ltd

Boehringer Ingelheim International GmbH

Julphar Pharma Inc

United Laboratories International Holdings Limited

Tonghua Dongbao Pharmaceutical Co. Ltd.

Report Scope:

In this report, the GlobalShort-Acting InsulinMarket has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Short-Acting Insulin Market,By Drugs:

Apidra
Novolog
Humalog
Novolin
Others

Short-Acting Insulin Market,By Application:

Type 1 Diabetes
Type 2 Diabetes

Short-Acting Insulin Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Short-Acting Insulin Market.

Available Customizations:

Global Short-Acting Insulin market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1.Product Overview

1.1.Market Definition
1.2.Scope of the Market
- 1.2.1.Markets Covered
- 1.2.2.Years Considered for Study
- 1.2.3.Key Market Segmentations

2.Research Methodology

2.1.Objective of the Study
2.2.Baseline Methodology
2.3.Key Industry Partners
2.4.Major Association and Secondary Sources
2.5.Forecasting Methodology
2.6.Data Triangulation Validation
2.7.Assumptions and Limitations

3.Executive Summary

3.1.Overview of the Market
3.2.Overview of Key Market Segmentations
3.3.Overview of Key Market Players
3.4.Overview of Key Regions/Countries
3.5.Overview of Market Drivers, Challenges, Trends

4.Global Short-Acting Insulin Market Outlook

4.1.Market Size Forecast
- 4.1.1.By Value
4.2.Market Share Forecast
- 4.2.1.By Drugs (Apidra, Novolog, Humalog, Novolin, Others)
- 4.2.2.By Application (Type 1 Diabetes, Type 2 Diabetes)
- 4.2.3.By Region
- 4.2.4.By Company (2023)
4.3.Market Map
- 4.3.1.By Drugs
- 4.3.2.By Application
- 4.3.3.By Region

5.Asia Pacific Short-Acting Insulin Market Outlook

5.1.Market Size Forecast
- 5.1.1.By Value
5.2.Market Share Forecast
- 5.2.1.By Drugs
- 5.2.2.By Application
- 5.2.3.By Country
5.3.Asia Pacific: Country Analysis
- 5.3.1.China Short-Acting Insulin Market Outlook
  - 5.3.1.1.Market Size Forecast
    - 5.3.1.1.1.By Value
  - 5.3.1.2.Market Share Forecast
    - 5.3.1.2.1.By Drugs
    - 5.3.1.2.2.By Application
- 5.3.2.India Short-Acting Insulin Market Outlook
  - 5.3.2.1.Market Size Forecast
    - 5.3.2.1.1.By Value
  - 5.3.2.2.Market Share Forecast
    - 5.3.2.2.1.By Drugs
    - 5.3.2.2.2.By Application
- 5.3.3.Australia Short-Acting Insulin Market Outlook
  - 5.3.3.1.Market Size Forecast
    - 5.3.3.1.1.By Value
  - 5.3.3.2.Market Share Forecast
    - 5.3.3.2.1.By Drugs
    - 5.3.3.2.2.By Application
- 5.3.4.Japan Short-Acting Insulin Market Outlook
  - 5.3.4.1.Market Size Forecast
    - 5.3.4.1.1.By Value
  - 5.3.4.2.Market Share Forecast
    - 5.3.4.2.1.By Drugs
    - 5.3.4.2.2.By Application
- 5.3.5.South Korea Short-Acting Insulin Market Outlook
  - 5.3.5.1.Market Size Forecast
    - 5.3.5.1.1.By Value
  - 5.3.5.2.Market Share Forecast
    - 5.3.5.2.1.By Drugs
    - 5.3.5.2.2.By Application

6.Europe Short-Acting Insulin Market Outlook

6.1.Market Size Forecast
- 6.1.1.By Value
6.2.Market Share Forecast
- 6.2.1.By Drugs
- 6.2.2.By Application
- 6.2.3.By Country
6.3.Europe: Country Analysis
- 6.3.1.France Short-Acting Insulin Market Outlook
  - 6.3.1.1.Market Size Forecast
    - 6.3.1.1.1.By Value
  - 6.3.1.2.Market Share Forecast
    - 6.3.1.2.1.By Drugs
    - 6.3.1.2.2.By Application
- 6.3.2.Germany Short-Acting Insulin Market Outlook
  - 6.3.2.1.Market Size Forecast
    - 6.3.2.1.1.By Value
  - 6.3.2.2.Market Share Forecast
    - 6.3.2.2.1.By Drugs
    - 6.3.2.2.2.By Application
- 6.3.3.Spain Short-Acting Insulin Market Outlook
  - 6.3.3.1.Market Size Forecast
    - 6.3.3.1.1.By Value
  - 6.3.3.2.Market Share Forecast
    - 6.3.3.2.1.By Drugs
    - 6.3.3.2.2.By Application
- 6.3.4.Italy Short-Acting Insulin Market Outlook
  - 6.3.4.1.Market Size Forecast
    - 6.3.4.1.1.By Value
  - 6.3.4.2.Market Share Forecast
    - 6.3.4.2.1.By Drugs
    - 6.3.4.2.2.By Application
- 6.3.5.United Kingdom Short-Acting Insulin Market Outlook
  - 6.3.5.1.Market Size Forecast
    - 6.3.5.1.1.By Value
  - 6.3.5.2.Market Share Forecast
    - 6.3.5.2.1.By Drugs
    - 6.3.5.2.2.By Application

7.North America Short-Acting Insulin Market Outlook

7.1.Market Size Forecast
- 7.1.1.By Value
7.2.Market Share Forecast
- 7.2.1.By Drugs
- 7.2.2.By Application
- 7.2.3.By Country
7.3.North America: Country Analysis
- 7.3.1.United States Short-Acting Insulin Market Outlook
  - 7.3.1.1.Market Size Forecast
    - 7.3.1.1.1.By Value
  - 7.3.1.2.Market Share Forecast
    - 7.3.1.2.1.By Drugs
    - 7.3.1.2.2.By Application
- 7.3.2.Mexico Short-Acting Insulin Market Outlook
  - 7.3.2.1.Market Size Forecast
    - 7.3.2.1.1.By Value
  - 7.3.2.2.Market Share Forecast
    - 7.3.2.2.1.By Drugs
    - 7.3.2.2.2.By Application
- 7.3.3.Canada Short-Acting Insulin Market Outlook
  - 7.3.3.1.Market Size Forecast
    - 7.3.3.1.1.By Value
  - 7.3.3.2.Market Share Forecast
    - 7.3.3.2.1.By Drugs
    - 7.3.3.2.2.By Application

8.South America Short-Acting Insulin Market Outlook

8.1.Market Size Forecast
- 8.1.1.By Value
8.2.Market Share Forecast
- 8.2.1.By Drugs
- 8.2.2.By Application
- 8.2.3.By Country
8.3.South America: Country Analysis
- 8.3.1.Brazil Short-Acting Insulin Market Outlook
  - 8.3.1.1.Market Size Forecast
    - 8.3.1.1.1.By Value
  - 8.3.1.2.Market Share Forecast
    - 8.3.1.2.1.By Drugs
    - 8.3.1.2.2.By Application
- 8.3.2.Argentina Short-Acting Insulin Market Outlook
  - 8.3.2.1.Market Size Forecast
    - 8.3.2.1.1.By Value
  - 8.3.2.2.Market Share Forecast
    - 8.3.2.2.1.By Drugs
    - 8.3.2.2.2.By Application
- 8.3.3.Colombia Short-Acting Insulin Market Outlook
  - 8.3.3.1.Market Size Forecast
    - 8.3.3.1.1.By Value
  - 8.3.3.2.Market Share Forecast
    - 8.3.3.2.1.By Drugs
    - 8.3.3.2.2.By Application

9.Middle East and Africa Short-Acting Insulin Market Outlook

9.1.Market Size Forecast
- 9.1.1.By Value
9.2.Market Share Forecast
- 9.2.1.By Drugs
- 9.2.2.By Application
- 9.2.3.By Country
9.3.MEA: Country Analysis
- 9.3.1.South Africa Short-Acting Insulin Market Outlook
  - 9.3.1.1.Market Size Forecast
    - 9.3.1.1.1.By Value
  - 9.3.1.2.Market Share Forecast
    - 9.3.1.2.1.By Drugs
    - 9.3.1.2.2.By Application
- 9.3.2.Saudi Arabia Short-Acting Insulin Market Outlook
  - 9.3.2.1.Market Size Forecast
    - 9.3.2.1.1.By Value
  - 9.3.2.2.Market Share Forecast
    - 9.3.2.2.1.By Drugs
    - 9.3.2.2.2.By Application
- 9.3.3.UAE Short-Acting Insulin Market Outlook
  - 9.3.3.1.Market Size Forecast
    - 9.3.3.1.1.By Value
  - 9.3.3.2.Market Share Forecast
    - 9.3.3.2.1.By Drugs
    - 9.3.3.2.2.By Application